Other studies have also suggested a supplementary role for altered NfL levels, either in plasma or cerebrospinal fluid, to the known PD-pathognomonic biomarker α-synuclein for differentiating patients with PD patients from non-PD controls [20,21]. The gene discussed is SNCA; the disease is Parkinson disease.